Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Essilor: Procedures for Requesting or Viewing Proxy Information for the Ordinary Annual Meeting on April 24, 2018


Posted on: 03 Apr 18

Procedures for Requesting or Viewing
Proxy Information for the Ordinary
Annual Meeting on April 24, 2018

PDF Version of the news release

Charenton-le-Pont, France (April 3, 2018 - 6:00 p.m. CEST) - Shareholders are advised that the Ordinary Annual Meeting will be held on Tuesday, April 24, 2018 at 10:30 a.m. CEST at the Maison de la Mutualité - 24, rue Saint-Victor - 75005 Paris - France.

The preliminary notice of meeting, published in the Bulletin des Annonces Légales Obligatoires
on March 9, 2018, contains information on the agenda, the proposed resolutions and the procedures for attending and voting.

Proxy information may be viewed in the Investors section of the Essilor corporate website at www.essilor.com: "Annual Shareholders' Meetings".

As provided for in Articles R.225-88 and R.225-89 of the French Commercial Code, any shareholder may consult the proxy documents and information, as described in Article R.225-83 of the French Commercial Code, at Company headquarters (147 rue de Paris - 94220 Charenton-le-Pont - France) or request that such documents be sent to him or her, by writing to:
Société Générale - Service des Assemblées - CS 30812 - 44308 Nantes Cedex 03 - France. 

About Essilor
Essilor International (Compagnie Générale d'Optique) ("Essilor") is the world's leading ophthalmic optics company. Essilor designs, manufactures and markets a wide range of lenses to improve and protect eyesight. Its mission is to improve lives by improving sight. To support this mission, Essilor allocates more than €200 million to research and innovation every year, in a commitment to continuously bring new, more effective products to market. Its flagship brands are Varilux®, Crizal®, Transitions®, EyezenTM, Xperio®, Foster Grant®, BolonTM and Costa®. It also develops and markets equipment, instruments and services for eyecare professionals.
Essilor reported consolidated revenue of around €7.5 billion in 2017 and employs approximately 67,000 people worldwide. It markets its products in more than 100 countries and has 34 plants, 481 prescription laboratories and edging facilities, as well as 4 research and development centers around the world. For more information, please visit www.essilor.com.
The Essilor share trades on the Euronext Paris market and is included in the Euro Stoxx 50 and CAC 40 indices. 
Codes and symbols: ISIN: FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.

------------------------
Investor Relations and Financial Communications
Phone: +33 (0)1 49 77 42 16

Attachment:

http://www.globenewswire.com/NewsRoom/AttachmentNg/9478f488-d0c6-44fc-8ff0-ca3e6a77aacd

GlobeNewswire
globenewswire.com

Last updated on: 04/04/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.